Introduction
Sepsis is defined as an invasion of microorganisms and/or their toxins into the blood associated the reaction of the organism to this invasion.
Helge Knut Schumacher 
Research questions
The following questions were analysed: is Drotrecogin alfa (activated) (DAA) effective in the treatment of patients with severe sepsis and a 
Methods
Only studies with adult patients are included. There are no other exclusion criteria. A systematic literature search is performed by the German versitätsmedizin Berlin, Berlin, Deutschland
Institute of Medical Documentation and Information (DIMDI). The literature search yielded as a total of 847 hits. After screening of the abstracts, 165 medical and 101 economic publications were chosen for full text appraisal.
Results
Therapy with DAA appears to be cost effective in reducing 28-day-mortality in patients with severe sepsis and a high risk of death. A high risk of death is indicated by the presence of multiorgan failure (≥2) and/or an APACHE-II-Score ≥25. Therapy with DAA is not associated with a longterm reduction of mortality at later follow-up assessments. Therapy with DAA is not associated with a long-term reduction of mortality at later follow-up assessments. Therapy with DAA is cost-effective in patients with multiorgan failure and/or an APACHE II Score (≥25). In patients with a lower risk of death, DAA is not cost-effective. Costs associated with bleeding events have been rarely included in cost calculations.
Discussion
DAA appears to reduce mortality in patients with severe sepsis and a high risk of death, but not in patients with a low risk of death. Bleeding events and mortality are considerable higher in studies in the usual care setting compared to clinical trials. In a number of subgroup analyses, both retrospectively and prospectively performed, DAA was not significantly associated with improved survival. The role of concurrent therapy with heparin is unclear, as DAA was only effective in reducing mortality in patients without heparin. There was no significant long-term survival benefit associated with DAA beyond the initial 28 days. Also, there is a lack of studies assessing prospectively functional ability, health-related quality of life, and morbidity in the long-term. In the subgroup of patients with a high risk of death, therapy with DAA ranges at the top level of generally accepted costs per LYG or QALY, in the subgroup of patients with low risk of death, cost effectiveness ratios were higher than those accepted for resource allocation.
Conclusion
Due to the lack of effectiveness of DAA in patients with severe sepsis and a low risk of death as well as with regard to the high bleeding rates in the usual care setting, indication for DAA therapy. In those subgroups with no significant survival benefit, prospective studies with adequate sample size are needed. With regard to the heterogeneity of severe sepsis, comorbidity and concurrent medication have to be taken into account in further studies. Studies with alternative study designs, for example studies comparing heparin alone or in combination with DAA to placebo, as well as studies conducted by different researchers are needed. Costs induced by bleeding events should also be taken into account in future studies, as bleeding events are the major complication associated the DAA therapy. 
Zusammenfassung Einleitung

Scientific background
Severe sepsis is a systemic inflammatory reaction (systemic inflammatory response syndrome, SIRS), associated with acute dysfunction or failure of one or more organ systems. Failure of organ systems such as the renal or the cardiovascular system may be the consequence of a pathophysiological overreaction of the body to the infection. The clinical outcome depends on both the aggressiveness of the underlying infectious agent as well as on the immune system of the patient and its reaction to the agent. There are three categories for the severity of sepsis: sepsis with proven or assumed infection, severe sepsis with organ dysfunction and septic shock with circulatory failure. 
Research questions
Methods
Only trials with adults were included into this assessment. Besides this confinement no other limitations concerning the target population were used. In addition to the literature search of the DIMDI on the topic "drotrecogin alfa activated in the treatment of severe sepsis in adults" the authors have undertaken additional research in Cochrane databases. The hits have been audited on their relevance for the topic of this assessment. From this search further publications have been chosen from their abstract and/or title. The abstracts were screened systematically. Publications in other languages than German or English were excluded as well as publications focusing on other interventions and case reports. Checklists have been used for the exclusions.
Results
Medical part
The systematic literature search has yielded a total of 847 publications with regard to activated Protein C. Out of these, 165 publications were considered relevant from the medical perspective and were chosen for further investigation in full text documents. Three other relevant publications were extracted from references. Based on the research, 36 publications were included and 132 publications excluded. The included publications consisted of one HTA, of one guidance, three randomised controlled trials (RCT), and eleven phase IV trials/compassionate use studies. As they reported only the results of two of the three RCT, seven systematic reviews were excluded. The HTA report published in 2005 and the NICE Guidance published in 2004 summarized the evidence with regard to DAA in patients with severe sepsis. In the HTA by Green et al. [7] the authors considered therapy with DAA to be effective in comparison to placebo. With regard to the subgroup analyses performed, therapy with DAA was deemed effected in the subgroup of patients with multiorgan failure (≥2). The authors assumed therapy with DAA to be effective not only during the initial 28 days of the PROWESS trial but also after three months. This assumption was apparently based on data provided to NICE by the manufacturer, Eli Lilly. However, in a publication by Angus et al. [1] based on the retrospective long-term follow-up of the PROWESS study, there were no significant differences in mortality between the intervention group and the control group after three months and at subsequent follow-up assessments. The authors of the HTA discussed the numerous subgroup analyses of the PRO-WESS study performed both prospectively and retrospectively. As adverse events of the PROWESS study, the authors described a non-significantly increased incidence of bleeding events in the intervention group. In addition, the authors summarized open research questions with regard to DAA. Similar conclusions to those of the HTA were reached in the NICE guidance.
The two RCT with regard to the primary endpoint of 28-day mortality in patients with severe sepsis showed inconsistent results. The PROWESS study showed a significant reduction in 28-day mortality with DAA compared to placebo in patients with severe sepsis and a mixed risk of death (25% vs. 34%; relative risk reduction 19.4%, 95% CI 6.6-30.5%; absolute risk reduction 6.1%). The AD-DRESS study showed no significant difference in the 28-day mortality with DAA in comparison to placebo in patients with severe sepsis and low risk of death (18.5% vs. 17.0%; relative risk 1.08, 95% CI 0.92 to 1.28). In the retrospective follow-up assessment of the PROWESS study, no differences in mortality were observed after three, six, twelve months and 2.5 years, respectively. In the subgroup analyses of the PROWESS study, a significant reduction in mortality associated with DAA therapy was observed in the following subgroups: </≥65 years of age, ≥75 years, men, caucasian, region USA/Canada, no congestive heart failure, cancer, COPD, no prior surgery, lung as infection site and/community acquired pneumonia, gram positive bacteria, DIC, protein C deficiency, prothrombin time >14.5 to 100 s, partial thromboplastin time >37-74 s, platelets <140,000/µl, IL 6 ≥1000 pg/ml, mechani-cal ventilation, vasopressor support, high APA-CHE II (≥25) and high SOFA-Score (>11), as well as multiorgan failure (≥2 organ systems).
In the following subgroups no significant reduction in mortality was observed: women, non-caucasian, region Europe/other, congestive heart failure, no cancer, no COPD, prior surgery, abdomen, urinary tract/other as infection site, gram negative bacteria or no microorganism, no DIC, no protein C deficiency, prothrombin time ≤14.5 s, partial thromboplastin time ≤37 s and 74 to 100 s, platelets ≥140,000/µl, IL 6 <1000 pg/mL, no mechanical ventilation, no vasopressor support, low APACHE II (<25) and SOFA-Score (<11). Serious bleeding events were the most relevant adverse events under therapy with DAA. Whereas the PROWESS study did not show any difference in serious bleeding events between intervention and placebo groups (3.5% vs. 2.0%; P=0.06), the ADDRESS study showed a significantly increased bleeding rate in patients treated with DAA compared to placebo (3.9% vs. 2.2%; P = 0.01). The increased risk of bleeding associated with DAA led to the early stop of the ADDRESS study, as well as the lack of survival benefit in the treatment group. In most open-label and compassionate use studies, a higher mortality was observed compared to the PROWESS study. In addition, bleeding rates were increased in studies in the usual care setting compared to clinical trials. The risk of bleeding increased with decreasing level of controlled trial design (clinical trials, open-label studies, compassionate use studies). The ENHANCE study as the largest open-label, single arm trial reported a bleeding rate twice as high in the intervention group compared to the PROWESS data (6.5% vs. 3.5%, respectively).
Ecomic part
The therapy regimen of rhAPC did not lead to an increased resource use except the drug cost in the trial of Angus [2] and colleagues. Focussing on the outcome at day 28 rhAPC costs 160,000 USD per life saved. In a reference case 48,800 USD per QALY were calculated. These findings are limited because their source is the PROWESS trial alone. The transfer of the observed effects is in so far restricted. Betancourt et al. [3] show that a strict limitation to a greater number or dysfunctional organs leads to a better mortality outcome, more saved lives at lower costs. Even the bleeding events do not change this result. [9] with respect to the presentation of the research methods than Fowler et al. [5] who deliver the "better" QALY. The cost effectiveness in European studies is higher than in Canada or the US because of the limitation to multiorgan dysfunction. This constraint narrows the cohort to the more severe patients with a higher mortality benefit from rhAPC. The findings of a second study by Green et al. [6] 
Discussion
The PROWESS trial showed a significant reduction in 28-day-mortality associated with the use of DAA in comparison to placebo in patients with severe sepsis and a mixed risk of death. The ADDRESS trial did not show a significant reduction in mortality but showed an increased risk of bleeding associated with DAA. In the ENHANCE study, a phase-IV-study, a bleeding rate twice as high as the bleeding rate in PROWESS study was observed. In PROWESS study, numerous subgroup analyses were performed. A significant survival benefit associated with DAA was reported for 23 subgroups, and no survival benefit for 27 subgroups. A significant treatment benefit seemed to be associated with an increased disease severity. Some of the subgroups were prospectively defined, others retrospectively. In general, subgroup analyses lead to a number of methodological problems and should only be used as hypothesis generating. The major adverse events observed during therapy with DAA were serious bleeding events. In most open-label and compassionate use studies, the risk of bleeding was significantly higher than in the PROWESS trial. Overall, the risk of bleeding seemed to be inversely related to controlled study design. Also, the risk of bleeding was associated with prior surgery and/or the presence of coagulopathy. Prospective evaluations of long-term morbidity induced by serious bleeding events are required. Also, interventions needed to stop bleeding need to be assessed. In the retrospective long-term follow-up of the PROWESS trial, no significant differences in mortality were found between intervention-and control group. Prospectively planned studies with sufficient long-term follow-up assessments and with "intention-to-treat" analysis are needed. As organ systems may be permanently damaged in some patients, an expert panel recommen-ded a follow-up period of at least three to six months. In addition, other endpoints have not been determined sufficiently, such as functional ability, health-related quality of life, and morbidity following severe sepsis. The study population of the PROWESS study was heterogeneous, as common in severe sepsis. Comorbidity and concurrent medication may influence coagulation status as well as overall mortality risk and need to be taken into account when assessing the efficacy of DAA. The role of concurrent use of heparin and/or other anticoagulants in the treatment of severe sepsis remains unclear. The relative risk reduction associated with DAA was only significant in patients without heparin therapy (25%). The prognosis after a period of severe sepsis differs considerably between different countries, e.g. the hospital mortality in England/Wales was approximately twice as high as in the US. Concentrating on the whole potentially to be treated group the cost efficiencies range on to top level of accepted interventions by the third party payers. Narrowing the population down to the fraction with a high lethality (MOV or APACHE-II-Score ≥25) the trials at hand report that the therapy is cost efficient. The calculated cost efficiencies then lie well below generally accepted thresholds. A treatment of all possible septic patients would have shifted the cost effectiveness into an unacceptable range. The relevant adverse event of bleedings has not been dealt with in all studies. Only three studies have reported at least the fact that bleedings occur. Calculating them into costs was often not considered. A real adjustment of the cost effectiveness might have altered the cost effectiveness in an unwished way.
Conclusions/recommendations
To conclude, therapy with DAA seems to be associated with a significant reduction in 28-day mortality compared to placebo in patients with severe sepsis and a high risk of death. No significant survival benefit was observed in patients with severe sepsis and a low risk of death. The study assessing the effectiveness of DAA in patients with low risk of death was stopped earlier as there was an increased risk of bleeding in the treatment group. In the usual care setting, both mortality and bleeding rates were increased in comparison to the clinical trial setting. Also, the role of concurrent heparin and other anticoagulants remains unclear.
Further research is required with regard to the following issues: long-term effect of DAA on mortality, morbidity, health-related quality of life, and resource use. In addition, effectiveness of DAA in the treatment of severe sepsis needs to be determined in studies with adequate sample size for those subgroups with a lack of survival benefit. Also, studies should stratify according to any underlying disease. Alternative designs, for example studies with multiple arms comparing DAA with heparin alone or in combination, are needed, as well as studies by different research. 
Kurzfassung 1. Gesundheitspolitischer Hintergrund
Methodik
Es werden nur Studien mit Erwachsenen eingeschlossen, ansonsten wird keine Einschränkung der Zielpopulation vorgenommen. Neben der vom DIMDI durchgeführten systematischen Literaturrecherche zum Thema "Drotrecogin alfa" (aktiviert) bei der Behandlung der schweren Sepsis bei Erwachsenen in Bezug auf deutsche und englische Literatur wird zusätzlich auf Basis der im Anhang aufgeführten Schlagworte eine Recherche in COCHRANE-Datenbanken durchgeführt. Dann werden die Treffer einzeln auf Relevanz für das vorliegende Thema "DAA bei der Behandlung der schweren Sepsis bei Erwachsenen" überprüft. Nach Titel und/oder "Abstract" werden dadurch Publikationen zur weiteren Analyse als Volltext ausgewählt. Für den ökonomischen Teil werden die "Abstracts" auf Basis der Themenstellung systematisch durchgesehen. Dabei werden Publikationen, die nicht in englischer oder deutscher Sprache vorhanden sind, Publikationen, die auf andere Verfahren fokussieren und Fallbeschreibungen (case reports) zu einzelnen medizinischen Fällen ausgeschlossen. Für den Ein-und Ausschluss werden Checklisten genutzt.
Ergebnisse
Medizinischer Teil
Die systematische Literaturrecherche identifizierte insgesamt 847 themenbezogene Publikationen. Die Sichtung dieser Treffer nach Titel und/oder "Abstract" ergab 165
Publikationen für den medizinischen Teil, die zur weiteren Analyse als Volltext ausgewählt wurden. Bei der Durchsicht der Volltexte wurden zusätzlich drei weitere relevante Publikationen aus Referenzen herausgesucht. Aufgrund der Relevanz für die vorliegende Fragestellung sowie der methodischen Qualität wurden für den medizinischen Teil insgesamt 36 Publikationen ein-und 132 Publikationen ausgeschlossen. Unter den eingeschlossenen Publikationen befanden sich ein HTA-Bericht, eine "Guidance", drei randomisierte kontrollierte Studien (RCT) und elf Phase-V-Studien/Anwendungsbeobachtungen/"Compassionate Use reports". Es wurden sieben systematische Reviews ausgeschlossen, da sie lediglich die Ergebnisse von zwei bis drei RCT berichteten und keine zusätzlichen Informationen zur Effektivität enthielten. Es wurde je ein HTA-Bericht von 2005 und eine National Institute for Clinical Excellence (NICE) -"Guidance" von 2004 zur Therapie mit DAA bei Patienten mit schwerer Sepsis gefunden und bewertet. Im HTA-Bericht von Green et al. [7] wurde die Therapie mit DAA plus supportive Therapie im Vergleich zu supportiver Therapie allein als effektiv bewertet. Nach Betrachtung der PROWESS-Subgruppenanalysen wurde die Therapie mit DAA vor allem in der Subgruppe der Patienten mit einer höheren Zahl an versagenden Organsystemen (≥2) als effektiv eingeschätzt. Der Überlebensvorteil von DAA wurde allerdings nicht nur für den 28-Tage-Zeitraum beschrieben, sondern auch als längerfristig nach drei Monaten angenommen. Dies war, soweit aus dem HTA-Bericht ersichtlich, offensichtlich auf Daten begründet, die vom Hersteller Eli Lilly beim NICE eingereicht worden waren. In der Publikation von Angus et al. [1] zur retrospektiv erfolgten Nachbeobachtung der PROWESS-Studie zeigte sich kein signifikanter Überlebensvorteil in der Interventions-im Vergleich zur Placebogruppe zum Zeitpunkt 90 Tage und zu späte-ren Zeitpunkten. Die Autoren des HTA-Berichts selbst wiesen auf die Problematik der zum Teil prospektiv und zum Teil retrospektiv erfolgten, zahlreichen Subgruppenanalysen hin. Als unerwünschte Nebenwirkungen der PROWESS-Studie beschrieben die Autoren eine nicht-signifikant erhöhte Inzidenz im Auftreten von Blutungen in der Interventionsgruppe. Ebenso wiesen sie auf die noch offenen Forschungsfragen hin. In der NICE-"Guidance" (2004) wurden ähnliche Schlussfolgerungen getroffen. Die zwei RCT mit der primären Fragestellung zur Mortalität unter Therapie mit DAA bei Patienten mit schwerer Sepsis ergaben uneinheitliche Ergebnisse. Die PROWESS-Studie zeigte eine signifikante Reduktion der 28-Tage-Mortalität im Vergleich zu Placebo bei Patienten mit schwerer Sepsis und kombiniertem Letalitätsrisiko (25% vs. 34%; relative Risikoreduktion 19,4%, 95% KI 6,6 bis 30,5%; absolute Risikoreduktion 6,1%). Die ADDRESS-Studie zeigte keinen signifikanten Unterschied in der 28-Tage-Mortalität unter DAA im Vergleich zu Placebo bei Patienten mit schwerer Sepsis und geringem Letalitätsrisiko (18,5% vs. 17,0%; relatives Risiko 1,08, 95% KI 0,92 bis 1,28). Im retrospektiv erfassten Langzeit-Verlauf der PROWESS-Studie ergab sich kein Unterschied in der Mortalität zu den Zeitpunkten drei, sechs, zwölf Monate bzw. 2,5 Jahre.
In den Subgruppenanalysen der PROWESS-Studie zeigte sich in folgenden Subgruppen eine signifikant verringerte Mortalität durch die Therapie mit DAA: </≥65 Jahre bzw. ≥75 Jahre, Männer, Kaukasier, Region USA/Kanada, keine Herzinsuffizienz, Tumorerkrankung, COPD, keine Operation, Infektionsherd Lunge bzw. Pneumonie (community-acquired pneumonia), Erreger grampositiv, DIC, Protein-C-Mangel, Quick >14,5 bis 100 s, PTT >37 bis 74 s, Thrombozyten <140.000/µl, IL 6 ≥1000 pg/mL, mechanische Ventilation, Vasopressoren nicht erkennbar, höherer APACHE II (≥25) und SOFA-Score, und Multiorganversagen (≥ zwei Organe zusammengefasst). In folgenden Subgruppen zeigte sich keine signifikante Reduktion der Mortalität durch DAA: Frauen, Nicht-Kaukasier, Region Europa/sonstige, Herzinsuffizienz, keine Tumorerkrankung, keine COPD, vorausgegangene Operation, Infektionsherd Abdomen, Harnwege/sonstige, Erreger gramnegativ, gemischt oder kein Mikroorganismus, keine DIC, kein Protein-C-Mangel, Quick ≤14,5 s, PTT ≤37 s und 74 bis 100 s, Thrombozytenzahl ≥140.000/µl, IL 6 <1000 pg/mL, keine mechanische Ventilation, keine Vasopressoren, niedriger APACHE II (≥25) und SOFAScore (<11). Schwere Blutungen waren die wesentlichen SUE unter Therapie mit DAA. Während die PROWESS-Studie keinen signifikanten Unterschied im Auftreten von schweren Blutungen zwischen Interventions-und Kontrollgruppe ergab (3,5% vs. 2,0%; P=0,06), war die Blutungsrate in der ADDRESS-Studie signifikant in der Interventionsgruppe erhöht (3,9% vs. 2,2%; P=0,01). Die erhöhte Blutungsrate hatte zusammen mit dem fehlenden Nachweis einer Reduktion der Mortalität zu einem vorzeitigen Abbruch der ADDRESS-Studie geführt. Die Mortalität bei Patienten mit schwerer Sepsis war in den meisten "Open Label"-und "Compassionate Use"-Studien höher als in der PROWESS-Studie. Ebenso war die Blutungsrate beim Einsatz von DAA im klinischen Alltag höher als in der PROWESS-Studie und stieg mit Abnahme des kontrollierten Designs an (klinische, "Open Label"-, "Compassionate Use"-Studien). Die ENHANCEStudie als größte "Open Label", "Single Arm" Phase-IVStudie zeigte eine etwa doppelt so hohe Blutungsrate im Vergleich zur PROWESS-Studie (6% vs. 3,5%).
Ökonomischer Teil
Der Einsatz von DAA in der Studie für die USA von Angus et al. [2] führte nicht zu einem erhöhten Ressourcenverbrauch abgesehen von den eigentlichen Beschaffungskosten. In der Betrachtung des 28-Tage "Outcomes" kostete DAA 160.000 USD pro gerettetem Leben. In einem konstruierten "Reference Case" kostete DAA 48.800 USD pro qualitätskorrigiertem Lebensjahr (QALY 
